PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10233213-1	1999	AIMS: To examine the effect of ticlopidine administration on the activities CYP2C19 and CYP3 A in vivo using omeprazole as a model substrate.	Ticlopidine	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94	
22651985-8	2012	Pre-incubation with recombinant human CYP3A4 not only caused degradation of clopidogrel and ticlopidine, but also increased cytotoxicity.	Ticlopidine	92-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44	
34503953-3	2021	Three CYP3A4 substrates, midazolam, ticlopidine, and diazepam, display non-Michaelis-Menten kinetics, form multiple primary metabolites, and are sequentially metabolized to secondary metabolites.	Ticlopidine	36-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12	
34503953-10	2021	Significance Statement The metabolism of midazolam, ticlopidine, and diazepam by CYP3A4 results in multiple metabolites and sequential metabolism.	Ticlopidine	52-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87	
35579824-6	2022	The relative contributions of different cytochromes P450 (CYPs), mainly CYP3A4 and CYP2B6, involved in esketamine/noresketamine clearance was captured correctly in the IN-PBPK model using the DDI clinical studies of intranasal esketamine with clarithromycin and rifampicin and a published DDI study of oral esketamine with ticlopidine.	Ticlopidine	323-334	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78	
21832258-4	2011	The non-CYP3A4 inhibitors diethyldithiocarbamate, quercetin, quinidine, sulfaphenazole, ticlopidine, and tranylcypromine were found to have substantially lower (maximum inhibition of <50%) or no apparent inhibitory effects in the HTS assay.	Ticlopidine	88-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14	
16855053-6	2006	In five of the six HLMs used, the percentage inhibition with ticlopidine and ketoconazole in the same incubation correlated with the combined % TNRs for CYP2B6 and CYP3A4.	Ticlopidine	61-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170	
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	192-197	
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	338-343